| [1] |
Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network [J]. Nat Rev Mol Cell Biol,2001,2(2): 127-137.
|
| [2] |
Spector NL, Blackwell KL. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2 positive breast cancer [J]. J Clin Oncol,2009,27(34): 5838-5847.
|
| [3] |
Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 [J]. N Engl J Med,2001,344(11): 783-792.
|
| [4] |
Murphy CG, Morris PG. Recent advances in novel targeted therapies for HER2-positive breast cancer [J]. Anticancer Drugs,2012,23(8): 765-776.
|
| [5] |
Awada A, Bozovic-Spasojevic I, Chow L. New therapies in HER2-positive breast cancer: a major step towards a cure of the disease? [J]. Cancer Treat Rev,2012,38(5): 494-504.
|
| [6] |
Arteaga CL, Sliwkowski MX, Osborne CK, et al. Treatment of HER2-positive breast cancer: current status and future perspectives [J]. Nat Rev Clin Oncol,2011,9(1): 16-32.
|
| [7] |
Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone,in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort [J]. Lancet,2010,375(9712): 377-384.
|
| [8] |
Buzdar AU,Ibrahim NK,Francis D,et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer [J]. J Clin Oncol,2005,23(16): 3676-3685.
|
| [9] |
Wong H, Leung R, Kwong A, et al. Integrating molecular mechanisms and clinical evidence in the management of trastuzumab resistant or refractory HER-2+ metastatic breast cancer [J]. Oncologist,2011,16(11): 1535-1546.
|
| [10] |
Gajria D, Chandarlapaty S. HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies [J]. Expert Rev Anticancer Ther,2011,11(2): 263-275.
|
| [11] |
Scaltriti M,Eichhorn PJ,Cortés J,et al. Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients[J]. Proc Natl Acad Sci U S A,2011,108(9): 3761-3766.
|
| [12] |
Lewis Phillips GD, Li G, Dugger DL, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibodycytotoxic drug conjugate [J]. Cancer Res,2008,68(22): 9280-9290.
|
| [13] |
Krop IE, Beeram M, Modi S, et al. Phase Ⅰ study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer [J]. J Clin Oncol,2010,28(16): 2698-2704.
|
| [14] |
Burris HA 3rd,Rugo HS, Vukelja SJ,et al. Phase Ⅱstudy of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy [J]. J Clin Oncol,2011,29(4): 398-405.
|
| [15] |
Krop IE, LoRusso P, Miller KD, et al. A phase Ⅱstudy of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab,lapatinib,an anthracycline,a taxane, and capecitabine [J]. J Clin Oncol,2012,30(26): 3234-3241.
|
| [16] |
Scheuer W, Friess T, Burtscher H, et al. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment of HER2-positive human xenofraft tumor models [J].Cancer Res,2009,69(24): 9330-9336.
|
| [17] |
Baselga J, Gelmon KA, Verma S, et al. Phase Ⅱtrial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy [J]. J Clin Oncol,2010,28(7): 1138-1144.
|
| [18] |
Baselga J, Swain SM. CLEOPATRA: a phase Ⅲevaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer[J]. Clin Breast Cancer,2010,10(6): 489-491.
|
| [19] |
Baselga J, Cortés J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer [J]. N Engl J Med,2012,366(2): 109-119.
|
| [20] |
Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer(NeoSphere): a randomised multicentre, open-label, phase 2 trial [J]. Lancet Oncol,2012,13(1): 25-32.
|
| [21] |
Schoeberl, B, Faber AC, Li D, et al. An ErbB3 antibody,MM121, is active in cancers with ligand-dependent activation[J]. Cancer Res,2010,70(6),2485-2494.
|
| [22] |
Gholam D, Chebib A, Hauteville D, et al. Combined paclitaxel and cetuximab achieved a major response on the skin metastases of a patient with epidermal growth factor receptor positive, estrogen receptor-negative, progesterone receptornegative and human epidermal growth factor receptor-2-negative(triple-negative) breast cancer [J]. Anti-cancer Drugs,2007,18(7): 835-837.
|
| [23] |
Xia W, Gerard CM, Liu L, et al. Combining lapatinib(GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells[J]. Oncogene,2005,24(41): 6213-6221.
|
| [24] |
Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer [J]. N Engl J Med,2006,355(26): 2733-2743.
|
| [25] |
Cameron D, Casey M, Press M, et al. A phase Ⅲrandomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses [J].Breast Cancer Res Treat,2008,112(3): 533-543.
|
| [26] |
Blackwell KL, Burstein HJ, Storniolo AM, et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer [J]. J Clin Oncol,2010,28(7): 1124-1130.
|
| [27] |
Johnston S, Pippen J Jr, Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer [J]. J Clin Oncol,2009,27(33): 5538-5546.
|
| [28] |
Baselga J, Bradbury I, Eidtmann H, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial [J].Lancet,2012,379(9816): 633-640.
|
| [29] |
Untch M,Loibl S,Bischoff J,et al. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial [J]. Lancet Oncol,2012,13(2): 135-144.
|
| [30] |
Rabindran SK, Discafani CM, Rosfjord EC, et al. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase [J]. Cancer Res,2004,64(11): 3958-3965.
|
| [31] |
Burstein HJ,Sun Y,Dirix LY,et al. Neratinib,an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer [J]. J Clin Oncol,2010,28(8): 1301-1307.
|
| [32] |
Minkovsky N,Berezov A. BIBW-2992,a dual receptor tyrosine kinase inhibitor for the treatment of solid tumors [J]. Curr Opin Investig Drugs,2008,9(12): 1336-1346.
|
| [33] |
Lin NU, Winer EP, Wheatley D, et al. A phase Ⅱstudy of afatinib (BIBW2992), an irreversible ErbB family bloker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab [J]. Breast Cancer Res,2012,133(3): 1057-1065.
|
| [34] |
Miller TW, Rexer BN, Garrett JT, et al. Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer [J]. Breast Cancer Res,2011,13(6): 224.
|
| [35] |
Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer [J]. New Engl J Med,2012,366(6): 520-529.
|
| [36] |
Mackey JR, Kerbel RS, Gelmon KA, et al. Controlling angiogenesis in breast cancer: a systematic review of antiangiogenic trials [J]. Cancer Treat Rev,2012,38(6): 673-688.
|
| [37] |
Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer [J]. N Engl J Med,2007,357(26): 2666-2676.
|
| [38] |
Gray R, Bhattacharya S, Bowden C, et al. Independent review of E2100: a phase Ⅲtrial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer [J]. J Clin Oncol,2009,27(30): 4966-4972.
|
| [39] |
Miles DW, Chan A, Dirix LY, et al. Phase Ⅲ study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer [J]. J Clin Oncol,2010,28(20): 3239-3247.
|
| [40] |
Robert NJ, Diéras V, Glaspy J, et al. RIBBON-1: randomized, doubleblind, placebo-controlled, phase Ⅲtrial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative,locally recurrent or metastatic breast cancer [J]. J Clin Oncol,2011,29(10): 1252-1260.
|
| [41] |
von Minckwitz G, Eidtmann H, Rezai M, et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer [J]. N Engl J Med,2012,366(4): 299-309.
|
| [42] |
Bear HD, Tang G, Rastogi P, et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer [J]. N Engl J Med,2012,366(4): 310-320.
|
| [43] |
Ranpura V, Hapani S, Wu S. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis[J]. JAMA,2011,305(5): 487-494.
|
| [44] |
王涛,江泽飞.乳腺癌分子靶向治疗进展、困境和出路[J/CD].中华乳腺病杂志: 电子版,2011,5(5): 517-524.
|
| [45] |
Robert NJ, Saleh MN, Paul D, et al. Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advancedbreast cancer: a phase Ⅲ, randomized,open-label trial [J]. Clin Breast Cancer,2011,11(2): 82-92.
|
| [46] |
Burstein HJ, Elias AD, Rugo HS, et al. Phase Ⅱstudy of sunitinib malate,an oral multitargeted tyrosine kinase inhibitor,in patients with metastatic breast cancer previously treated with an anthracycline and a taxane [J]. J Clin Oncol,2008,26(11): 1810-1816.
|
| [47] |
Baselga J,Segalla JG, Roché H, et al. Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer [J]. J Clin Oncol,2012,30(13): 1484-1491.
|
| [48] |
Erlichman C. Tanespimycin: the opportunities and challenges of targeting heat shock protein 90 [J]. Expert Opin Investig Drugs,2008,18(6): 861-868.
|
| [49] |
Modi S, Stopeck A, Linden H, et al. HSP90 inhibition is effective in breast cancer: a phase Ⅱtrial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab [J]. Clin Cancer Res,2011,17(15): 5132-5139.
|
| [50] |
Glendenning J, Tutt A. PARP inhibitors-current status and the walk towards early breast cancer [J]. Breast,2011,20(Suppl 3): S9-S12.
|
| [51] |
Wicki A, Rochlitz C. Targeted therapies in breast cancer [J].Swiss Med Wkly,2012,142: w13 550.
|
| [52] |
Tryfonopoulos D, Walsh S, Collins DM, et al. Scr: a potential target for the treatment of triple-negative breast cancer [J].Ann Oncol,2011,22(10): 2234-2240.
|
| [53] |
Herold CI, Chadaram V, Peterson BL, et al. Phase Ⅱtrial of dasatinib in patients with metastatic breast cancer using realtime pharmacodynamic tissue biomarkers of Src inhibition to escalate dosing[J]. Clin Cancer Res,2011,17(18): 6061-6070.
|
| [54] |
Somlo G, Atzori F, Strauss LC, et al. Dasatinib plus capecitabine for advanced breast cancer: safety and efficacy in phaseⅠstudy CA180004 [J]. Clin Cancer Res,2013,19(7): 1884-1893.
|
| [55] |
Peoples GE, Holmes JP, Hueman MT, et al. Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S.Military Cancer Institute Clinical Trials Group Study I-01 and I-02[J]. Clin Cancer Res,2008,14(3): 797-803.
|
| [56] |
Morse MA, Hobeika A,Osada T,et al. Long term disease-free survival and T cell and antibody responses in women with highrisk HER2+ breast cancer following vaccination against Her2[J]. J Transl Med,2007,5: 42.
|